S. P. Lowenthal

Lipid‐Lowering Efficacy, Safety, and Costs of a Large‐Scale Therapeutic Statin Formulary Conversion Program

P. O'Malley, Allen J. Taylor, K. Grace, 2001, Pharmacotherapy.

An exploratory patient centric analysis of the ELECT trial : a phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for patients (pts) with carcinoid syndrome (CS)

S. Braun, L. Duchateau, B. Mirakhur, 2017 .

Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs).

E. Wolin, A. Dasari, A. Phan, 2016, Clinical advances in hematology & oncology : H&O.

Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy: 2423

A. Vinik, R. Pommier, E. Wolin, 2015 .

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

A. Vinik, B. Mirakhur, M. Pavel, 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia

P. Ridker, N. Rifai, S. P. Lowenthal, 2001, Circulation.

Increased National Cholesterol Education Program (NCEP) Goal Attainment

S. P. Lowenthal, K. Chung, D. Beaudoin, 2001 .

Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC).

M. Kudo, E. Raymond, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of lanreotide autogel/depot (LAN) vs placebo (PBO) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients from the ELECT study

A. Vinik, B. Mirakhur, R. Pommier, 2016 .

Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropancreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.

A. Vinik, B. Mirakhur, M. Pavel, 2017 .

7118 An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma

P. Mainwaring, Se-Hoon Lee, H. Chung, 2009 .